 | | Vol. 10.35 – 6 September, 2022 |
| |
|
|
| Researchers successfully developed a two-in-one approach to generate non-viral, gene-specific targeted CAR-T cells through CRISPR–Cas9. Using the optimized protocol, they demonstrated feasibility in a preclinical study by inserting an anti-CD19 CAR cassette into the AAVS1 safe-harbour locus.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors described the tissue engineering of human thymus organoids from inducible pluripotent stem cells (iPSCs) that could support the de novo generation of a diverse population of functional human T cells.
[Nature Methods] |
|
|
|
| To discover promising shared tumor antigens that could be targeted via T cell receptor-based adoptive T cell therapy, scientists employed population-scale immunopeptidomics using quantitative mass spectrometry across approximately 1500 tumor and normal tissue samples.
[Science Translational Medicine] |
|
|
|
| In patients with non-small cell lung cancer treated with immune checkpoint blockade (ICB), napsin A was a self-antigen that elicited strong CD8+ T cell responses, with ICB responders harboring higher frequencies of these CD8+ T cells compared with nonresponders.
[Science Immunology] |
|
|
|
| Investigators performed an integrative analysis of single-cell transcriptomic profiling, paired T cell receptor sequencing, and spatial transcriptomic profiling on tuberous sclerosis complex associated tumors with mTORC1 hyperactivity.
[Nature Communications] |
|
|
|
| Resarchers developed and validated a CT-based radiomics score using 2272 gastric cancer patients to investigate the relationship between the radiomics imaging biomarker and the neutrophil-to-lymphocyte ratio in the tumor immune microenvironment.
[Nature Communications] |
|
|
|
| The authors provided a comprehensive characterisation of the inflammatory microenvironment in biliary tract carcinoma precursor lesions.
[British Journal of Cancer] |
|
|
|
| Investigators showed an elevated general expression of 17 pyroptosis-associated genes of tumor patients with high-immune-activity and a reduced pyroptosis in low-immune-activity tumors.
[Communications Biology] |
|
|
|
| In patients with chronic brucellosis, AIM2 expression was significantly lower, while Caspase-1 expression was significantly higher than that of healthy volunteers.
[Scientific Reports] |
|
|
|
| The frequencies of perforin-producing B cells in peripheral blood of heathy controls and systemic lupus erythematosus patients were detected by flow cytometry, and their correlation with the patient clinical and immunological features were analyzed.
[Clinical and Experimental Rheumatology] |
|
|
|
| Blood samples were collected from 35 children with severe hemophilia A. Children were divided into two groups: with factor (F)VIII inhibitors and without FVIII inhibitors. T cell excision circles and B cell excision circles were measured in peripheral blood.
[Pediatric Research] |
|
|
|
|
| Investigators summarize the current understanding of the role of inflammation in the pathogenesis of chronic kidney disease and its associated cardiovascular disease, and how this knowledge may translate into novel therapeutics.
[Nature Reviews Nephrology] |
|
|
|
| The authors provide a description of the emerging roles of glycoprotein-NMB (GPNMB) as an inducer of immunosuppression, with a particular focus on its role in mediating cancer progression by restraining pro-inflammatory innate and adaptive immune responses.
[Oncogene] |
|
|
|
| Scientists introduce immunosuppressive tumor microenvironment-remodeling strategies for improving immunotherapy based on nanosized drug delivery systems including triggering tumor cells to undergo immunogenetic cell death, applying tumor vaccine, and regulating intratumoral immune components.
[Acta Pharmacologica Sinica] |
|
|
|
|
| Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, announced that the US FDA has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of Mucopolysaccharidosis type I (MPS I).
[Immusoft] |
|
|
|
| Soligenix, Inc. announced that the US FDA has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage cutaneous T cell lymphoma.
[Soligenix, Inc.] |
|
|
|
|
|
|
|
| | Melanoma Institute Australia – Sydney, Australia |
|
|
|
| | STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada |
|
|
|
| | Dalhousie University – Halifax, Nova Scotia, Canada |
|
|
|
| | University of Michigan – Ann Arbor, Michigan, United States |
|
|
|
| | Gunderson Health System – La Crosse, WI, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
